What do we know about the reduction of Pt(IV) pro-dru

Journal of Inorganic Biochemistry
117, 220-229
DOI: 10.1016/j.jinorgbio.2012.06.013

Citation Report

#	Article	IF	Citations
1	Platinum(IV) Complexes Featuring Axial (1, 4â€“¹³C₂)Succinato Ligands â€“ Synthesis, Characterization, and Preliminary Âinvestigations in Cancer Cell Lysates. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2013, 639, 1613-1620.	0.6	7
2	Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation. Inorganic Chemistry, 2013, 52, 12276-12291.	1.9	347
3	Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand. Journal of Inorganic Biochemistry, 2013, 126, 46-54.	1.5	6
4	A Fluorescent Probe for Investigating the Activation of Anticancer Platinum(IV) Prodrugs Based on the Cisplatin Scaffold. Angewandte Chemie - International Edition, 2013, 52, 11785-11789.	7.2	41
5	Easy activation of the arylâ€“sulfur bond by platinum(ii). Chemical Communications, 2013, 49, 6421.	2.2	8
6	Maleimide-functionalised platinum(iv) complexes as a synthetic platform for targeted drug delivery. Chemical Communications, 2013, 49, 2249.	2.2	84
7	Theoretical Investigations and Density Functional Theory Based Quantitative Structureâ€“Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes. Journal of Medicinal Chemistry, 2013, 56, 330-344.	2.9	76
8	Platinum(IV) Prodrugs with Haloacetato Ligands in the Axial Positions can Undergo Hydrolysis under Biologically Relevant Conditions. Angewandte Chemie - International Edition, 2013, 52, 6059-6062.	7.2	80
9	Bulky N,N-(Di)alkylethane-1,2-diamineplatinum(II) Compounds as Precursors for Generating Unsymmetrically Substituted Platinum(IV) Complexes. Inorganic Chemistry, 2013, 52, 8151-8162.	1.9	32
12	N6-Benzyladenosine Derivatives as Novel N-Donor Ligands of Platinum(II) Dichlorido Complexes. Molecules, 2013, 18, 6990-7003.	1.7	12
13	Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin. Cancers, 2014, 6, 1487-1499.	1.7	5
14	trans,cis,cisâ€Bis(benzoato)dichlorido(cyclohexaneâ€1R,2Râ€diamine)platinum(IV): a Prodrug Candidate for the Treatment of Oxaliplatinâ€Refractory Colorectal Cancer. ChemMedChem, 2014, 9, 1299-1305.	1.6	22
15	Photoinduced Reduction of PtIVwithin an Anti-Proliferative PtIV-Texaphyrin Conjugate. Chemistry - A European Journal, 2014, 20, n/a-n/a.	1.7	17
16	Selective binding of naphthoquinone derivatives to serum albumin proteins and their effects on cytotoxicity. Chemico-Biological Interactions, 2014, 214, 10-17.	1.7	17
17	Homoleptic tris-cyclometalated platinum(<scp>iv</scp>) complexes: a new class of long-lived, highly efficient ³LC emitters. Chemical Science, 2014, 5, 1875-1880.	3.7	53
18	Kinetic characterization of the interactions of trans-dichloro-platinum(IV) anticancer prodrugs and a model compound with thiosulfate. Transition Metal Chemistry, 2014, 39, 127-133.	0.7	12
19	Metal-based anticancer chemotherapeutic agents. Current Opinion in Chemical Biology, 2014, 19, 144-153.	2.8	438
20	Copperâ€Free Clickâ€Chemistry Platform to Functionalize Cisplatin Prodrugs. Chemistry - A European Journal, 2014, 20, 6861-6865.	1.7	27

#	Article	IF	Citations
21	Characterization of the reaction products, kinetics and mechanism of oxidation of the drug captopril by platinum(iv) complexes. RSC Advances, 2014, 4, 7402.	1.7	29
22	Synthetic Methods for the Preparation of Platinum Anticancer Complexes. Chemical Reviews, 2014, 114, 4470-4495.	23.0	531
23	Pros and cons of bifunctional platinum(iv) antitumor prodrugs: two are (not always) better than one. Dalton Transactions, 2014, 43, 9813.	1.6	103
24	A novel cyclometallated Pt(ii)â€“ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation. Metallomics, 2014, 6, 622.	1.0	35
25	<scp>l</scp>-Selenomethionine reduces platinum(<scp>iv</scp>) anticancer model compounds at strikingly faster rates than<scp>l</scp>-methionine. Dalton Transactions, 2014, 43, 15328-15336.	1.6	23
26	Exploring the Scope of [Pt₂(4-FC₆H₄)₄(Î¼-SEt₂)₂] as a Precursor for New Organometallic Platinum(II) and Platinum(IV) Antitumor Agents. Organometallics, 2014, 33, 1740-1750.	1.1	25
27	Conjugates of Cisplatin and Cyclooxygenase Inhibitors as Potent Antitumor Agents Overcoming Cisplatin Resistance. ChemMedChem, 2014, 9, 1150-1153.	1.6	63
28	A New Entry to Asymmetric Platinum(IV) Complexes via Oxidative Chlorination. Inorganic Chemistry, 2014, 53, 9326-9335.	1.9	68
29	Cyclopalladated primary amines: A preliminary study of antiproliferative activity through apoptosis induction. European Journal of Medicinal Chemistry, 2014, 84, 530-536.	2.6	20
30	A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer Prodrugs. Journal of Medicinal Chemistry, 2014, 57, 6751-6764.	2.9	49
31	Platinum(IV) cisplatin derivative trans, cis, cis-bis(heptanoato)amine(cyclohexylamine)dichloridoplatinum(IV) has an enhanced therapeutic index compared to cisplatin for the treatment of non-small cell lung cancer. Inorganica Chimica Acta, 2014, 423, 215-219.	1.2	4
32	Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery. Metallomics, 2014, 6, 1324-1335.	1.0	170
33	A Photoactivatable Platinum(IV) Anticancer Complex Conjugated to the RNA Ligand Guanidinoneomycin. Chemistry - A European Journal, 2015, 21, 18474-18486.	1.7	27
34	Human Serum Albumin Conjugated Nanoparticles for pH and Redoxâ€Responsive Delivery of a Prodrug of Cisplatin. Chemistry - A European Journal, 2015, 21, 16547-16554.	1.7	50
35	Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Lightâ€Selective Toxicity towards Tumour Cells. Chemistry - A European Journal, 2015, 21, 15224-15234.	1.7	79
36	Synthesis of PtIV-Biomolecule Conjugates through Click Chemistry. European Journal of Inorganic Chemistry, 2015, 2015, 5335-5341.	1.0	5
37	Recent Advances in Platinum (IV) Complexâ€Based Delivery Systems to Improve Platinum (II) Anticancer Therapy. Medicinal Research Reviews, 2015, 35, 1268-1299.	5.0	84
38	Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs. Journal of Inorganic Biochemistry, 2015, 150, 1-8.	1.5	44

#	Article	IF	Citations
39	Isoquinoline derivatives Zn(II)/Ni(II) complexes: Crystal structures, cytotoxicity, and their action mechanism. European Journal of Medicinal Chemistry, 2015, 100, 68-76.	2.6	25
40	Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application. Journal of Biological Inorganic Chemistry, 2015, 20, 89-99.	1.1	47
41	On the Stability of Pt^{IV} Proâ€Drugs with Haloacetato Ligands in the Axial Positions. Chemistry - A European Journal, 2015, 21, 3108-3114.	1.7	45
42	Integrin-targeted delivery into cancer cells of a Pt(<scp>iv</scp>) pro-drug through conjugation to RGD-containing peptides. Dalton Transactions, 2015, 44, 202-212.	1.6	67
43	Reduction of ormaplatin by a dithiol model compound for the active site of thioredoxin: stopped-flow kinetic analysis. Transition Metal Chemistry, 2015, 40, 347-353.	0.7	12
44	Enhanced cancer cell killing of a Pt(iv) prodrug promoted by outer-sphere coordination with polyethyleneimines. Dalton Transactions, 2015, 44, 7135-7138.	1.6	5
45	The state-of-play and future of platinum drugs. Endocrine-Related Cancer, 2015, 22, R219-R233.	1.6	216
46	Unprecedented one-pot synthesis of an unsymmetrical cisplatin-based Pt(<scp>iv</scp>)â€“acetamidato complex. Chemical Communications, 2015, 51, 8051-8053.	2.2	21
47	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(iv)-based anticancer agents. Metallomics, 2015, 7, 1256-1264.	1.0	42
48	Bis- and Tris(carboxylato)platinum(IV) Complexes with Mixed Am(m)ine Ligands in thetransPosition Exhibiting Exceptionally High Cytotoxicity. European Journal of Inorganic Chemistry, 2015, 2015, 1700-1708.	1.0	6
49	Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs. Journal of Inorganic Biochemistry, 2015, 151, 132-142.	1.5	22
50	Characterization of the mechanism of reduction of trans-diamminetetrachloroplatinum(IV) by l-cysteine and dl-homocysteine. Transition Metal Chemistry, 2015, 40, 869-875.	0.7	7
51	Mono- and di-bromo platinum(iv) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity. Dalton Transactions, 2015, 44, 19918-19926.	1.6	24
52	Dihydroisoquinoline copper(ii) complexes: crystal structures, cytotoxicity, and action mechanism. RSC Advances, 2015, 5, 81313-81323.	1.7	18
53	Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance. ChemMedChem, 2015, 10, 183-192.	1.6	95
54	Oxidative halogenation of cisplatin and carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(<scp>iv</scp>) prodrugs. Dalton Transactions, 2015, 44, 119-129.	1.6	49
55	Tumor-targeting delivery of hyaluronic acidâ€“platinum(<scp>iv</scp>) nanoconjugate to reduce toxicity and improve survival. Polymer Chemistry, 2015, 6, 1541-1552.	1.9	40
56	Encapsulation of Pt(<scp>iv</scp>) prodrugs within a Pt(<scp>ii</scp>) cage for drug delivery. Chemical Science, 2015, 6, 1189-1193.	3.7	226

#	Article	IF	Citations
57	A platinum(IV)-based metallointercalator: synthesis, cytotoxicity, and redox reactions with thiol-containing compounds. Transition Metal Chemistry, 2015, 40, 31-37.	0.7	10
59	Glycosylated platinum(<scp>iv</scp>) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects. Dalton Transactions, 2016, 45, 11830-11838.	1.6	40
60	Platinum Complexes with Edda (Ethylenediamine -N, N - Diacetate) Ligands as Potential Anticancer Agents. Serbian Journal of Experimental and Clinical Research, 2016, 17, 285-296.	0.2	7
61	Intracellular delivery of chemical probes using a glutathione-responsive traceless tag. Chemical Communications, 2016, 52, 7715-7718.	2.2	14
62	Co-Delivery of Cisplatin Prodrug and Chlorin e6 by Mesoporous Silica Nanoparticles for Chemo-Photodynamic Combination Therapy to Combat Drug Resistance. ACS Applied Materials & Interfaces, 2016, 8, 13332-13340.	4.0	167
63	Platinum(<scp>iv</scp>) anticancer prodrugs â€“ hypotheses and facts. Dalton Transactions, 2016, 45, 12983-12991.	1.6	230
64	Selective speciation improves efficacy and lowers toxicity of platinum anticancer and vanadium antidiabetic drugs. Journal of Inorganic Biochemistry, 2016, 165, 56-70.	1.5	69
65	Activation of Platinum(IV) Prodrugs by Cytochrome c and Characterization of the Protein Binding Sites. Molecular Pharmaceutics, 2016, 13, 3216-3223.	2.3	30
66	Reactivity of the glutathione species towards the reduction of ormaplatin (or tetraplatin). Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4261-4266.	1.0	27
67	On the stability and biological behavior of cyclometallated Pt(IV) complexes with halido and aryl ligands in the axial positions. Bioorganic and Medicinal Chemistry, 2016, 24, 5804-5815.	1.4	17
68	The molecular shape and the field similarities as criteria to interpret SAR studies for fragment-based design of platinum(IV) anticancer agents. Correlation of physicochemical properties with cytotoxicity. Journal of Molecular Graphics and Modelling, 2016, 69, 39-60.	1.3	7
69	Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position. Scientific Reports, 2016, 6, 29367.	1.6	56
71	A kinetic analysis of oxidation of the antioxidant N-acetyl-l-cysteine (NAC) by Pt(IV) complexes. Transition Metal Chemistry, 2016, 41, 295-304.	0.7	3
72	Reduction of ormaplatin and cis-diamminetetrachloroplatinum(<scp>iv</scp>) by ascorbic acid and dominant thiols in human plasma: kinetic and mechanistic analyses. Dalton Transactions, 2016, 45, 11326-11337.	1.6	36
73	Effects of coordination mode of 2-mercaptothiazoline on reactivity of Au(I) compounds with thiols and sulfur-containing proteins. Journal of Inorganic Biochemistry, 2016, 165, 136-145.	1.5	14
74	Turbulent flow chromatography in combination with HPLC-ICP-MS for high-throughput analysis of free, intact metal based drugs in biomedical samples. Journal of Analytical Atomic Spectrometry, 2016, 31, 1811-1817.	1.6	5
75	Glutathione boosting the cytotoxicity of a magnetic platinum(<scp>iv</scp>) nano-prodrug in tumor cells. Chemical Science, 2016, 7, 2864-2869.	3.7	55
76	Recent updates in utilizing prodrugs in drug delivery (2013â€“2015). Expert Opinion on Drug Delivery, 2016, 13, 571-591.	2.4	13

#	Article	IF	Citations
77	Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs. Inorganic Chemistry, 2016, 55, 1580-1586.	1.9	35
78	Current and future potential of metallo drugs: Revisiting DNA-binding of metal containing molecules and their diverse mechanism of action. Inorganica Chimica Acta, 2016, 444, 1-22.	1.2	79
79	Pt(<scp>iv</scp>) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chemical Science, 2016, 7, 2381-2391.	3.7	155
80	Multifunctional Pt(II) Reagents: Covalent Modifications of Pt Complexes Enable Diverse Structural Variation and In-Cell Detection. Accounts of Chemical Research, 2016, 49, 56-66.	7.6	34
81	The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. Journal of Inorganic Biochemistry, 2016, 160, 264-274.	1.5	40
82	Behavior of platinum(<scp>iv</scp>) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. Metallomics, 2016, 8, 422-433.	1.0	39
83	Platinum-based drugs: past, present and future. Cancer Chemotherapy and Pharmacology, 2016, 77, 1103-1124.	1.1	646
84	Multi-scale imaging of anticancer platinum(<scp>iv</scp>) compounds in murine tumor and kidney. Chemical Science, 2016, 7, 3052-3061.	3.7	36
85	Antiproliferative activity of a series of cisplatin-based Pt(<scp>iv</scp>)-acetylamido/carboxylato prodrugs. Dalton Transactions, 2016, 45, 5300-5309.	1.6	42
86	Substituent effect and wavelength dependence of the photoinduced Ruâ€“O homolysis in the [Ru(bpy)2(py-SO3)]+-type complexes. Dalton Transactions, 2016, 45, 2897-2905.	1.6	15
87	Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands. Journal of Inorganic Biochemistry, 2016, 160, 85-93.	1.5	18
88	Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2017, 128, 45-55.	2.6	50
89	¹⁹⁵Pt NMR parameters as strong descriptors in oneâ€parameter QSAR models for platinumâ€based antitumor compounds. Magnetic Resonance in Chemistry, 2017, 55, 662-669.	1.1	1
90	Probing the Interactions of Cytotoxic [Pt(1S,2Sâ€DACH)(5,6â€dimethylâ€1,10â€phenanthroline)] and Its Pt^{IV} Derivatives with Human Serum. ChemMedChem, 2017, 12, 510-519.	1.6	8
91	Preparation of Pt(iv)-crosslinked polymer nanoparticles with an anti-detoxifying effect for enhanced anticancer therapy. Polymer Chemistry, 2017, 8, 2410-2422.	1.9	17
92	Comparative studies of oxaliplatin-based platinum(<scp>iv</scp>) complexes in different in vitro and in vivo tumor models. Metallomics, 2017, 9, 309-322.	1.0	60
93	Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. European Journal of Medicinal Chemistry, 2017, 142, 8-31.	2.6	316
94	EGFR-targeting peptide-coupled platinum(IV) complexes. Journal of Biological Inorganic Chemistry, 2017, 22, 591-603.	1.1	23

#	Article	IF	Citations
95	Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(<scp>iv</scp>) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)]. Dalton Transactions, 2017, 46, 7005-7019.	1.6	43
96	Hydrolysis in Acidic Environment and Degradation of Satraplatin: A Joint Experimental and Theoretical Investigation. Inorganic Chemistry, 2017, 56, 6013-6026.	1.9	20
99	Polymeric micelles for targeted tumor therapy of platinum anticancer drugs. Expert Opinion on Drug Delivery, 2017, 14, 1423-1438.	2.4	47
100	A computational mechanistic investigation into the reduction of Pt(<scp>iv</scp>) prodrugs with two axial chlorides by biological reductants. Chemical Communications, 2017, 53, 1413-1416.	2.2	19
101	Speciation of metal drugs, supplements and toxins in media and bodily fluids controls in vitro activities. Coordination Chemistry Reviews, 2017, 352, 473-498.	9.5	181
102	An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo. Chemical Science, 2017, 8, 2241-2250.	3.7	114
103	Platinum(<scp>iv</scp>) oxaliplatinâ€“peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells. Chemical Communications, 2017, 53, 11318-11321.	2.2	28
104	Research progress in modern structure of platinum complexes. European Journal of Medicinal Chemistry, 2017, 140, 349-382.	2.6	84
105	Biotinylated platinum(IV) complexes designed to target cancer cells. Journal of Inorganic Biochemistry, 2017, 176, 175-180.	1.5	38
106	Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid. Journal of Inorganic Biochemistry, 2017, 177, 1-7.	1.5	38
107	An unsymmetric cisplatin-based Pt(<scp>iv</scp>) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate. Dalton Transactions, 2017, 46, 14174-14185.	1.6	39
108	Reduction of Cisplatin and Carboplatin Pt(IV) Prodrugs by Homocysteine: Kinetic and Mechanistic Investigations. International Journal of Chemical Kinetics, 2017, 49, 681-689.	1.0	9
109	How to obtain Pt(<scp>iv</scp>) complexes suitable for conjugation to nanovectors from the oxidation of [PtCl(terpyridine)]⁺. Dalton Transactions, 2017, 46, 10246-10254.	1.6	11
110	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie - International Edition, 2017, 56, 11539-11544.	7.2	100
111	Exploring the Hydrolytic Behavior of the Platinum(IV) Complexes with Axial Acetato Ligands. Inorganic Chemistry, 2017, 56, 9851-9859.	1.9	21
112	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie, 2017, 129, 11697-11702.	1.6	22
113	Multifunctional Î±_vÎ²₆ Integrin-Specific Peptideâ€“Pt(IV) Conjugates for Cancer Cell Targeting. Bioconjugate Chemistry, 2017, 28, 2429-2439.	1.8	18
114	Co-delivery of paclitaxel and cisplatin with biocompatible PLGAâ€“PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models. Journal of Materials Chemistry B, 2017, 5, 6049-6057.	2.9	53

#	Article	IF	Citations
115	A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response. Cancer Letters, 2017, 385, 168-178.	3.2	42
117	In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines. Journal of Cancer, 2017, 8, 1733-1743.	1.2	2
118	Insight into the Electrochemical Reduction Mechanism of Pt(IV) Anticancer Complexes. Inorganic Chemistry, 2018, 57, 3411-3419.	1.9	33
119	The impact of whole human blood on the kinetic inertness of platinum(<scp>iv</scp>) prodrugs â€“ an HPLC-ICP-MS study. Dalton Transactions, 2018, 47, 5252-5258.	1.6	20
120	Triple action Pt(<scp>iv</scp>) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance. Chemical Science, 2018, 9, 4299-4307.	3.7	121
121	Structure elucidation and quantification of the reduction products of anticancer Pt(<scp>iv</scp>) prodrugs by electrochemistry/mass spectrometry (EC-MS). Analyst, The, 2018, 143, 1997-2001.	1.7	6
122	Intracellular glutathione-depleting polymeric micelles for cisplatin prodrug delivery to overcome cisplatin resistance of cancers. Journal of Controlled Release, 2018, 273, 30-39.	4.8	77
123	9. HEALTH BENEFITS OF VANADIUM AND ITS POTENTIAL AS AN ANTICANCER AGENT. , 2018, 18, 251-280.		34
124	Bioorthogonal Catalytic Activation of Platinum and Ruthenium Anticancer Complexes by FAD and Flavoproteins. Angewandte Chemie - International Edition, 2018, 57, 3143-3147.	7.2	68
125	Redox Potentials for Tetraplatin, Satraplatin, Its Derivatives, and Ascorbic Acid: A Computational Study. Inorganic Chemistry, 2018, 57, 951-962.	1.9	15
126	Reduction of platinum(IV) prodrug model complex trans-[PtCl2(CN)4]2â¯ by a peptide containing cysteine and methionine groups: HPLC and MS studies. Journal of Molecular Liquids, 2018, 252, 24-29.	2.3	9
127	Interactions of Ascorbic Acid with Satraplatin and its trans Analog JM576: DFT Computational Study. European Journal of Inorganic Chemistry, 2018, 2018, 1481-1491.	1.0	6
128	Anticancer platinumâ€based complexes with nonâ€classical structures. Applied Organometallic Chemistry, 2018, 32, e4228.	1.7	31
129	Spectroscopic Studies on Photoinduced Reactions of the Anticancer Prodrug, trans,trans,transâ€[Pt(N₃)₂(OH)₂(py)₂]. Chemistry - A European Journal, 2018, 24, 5790-5803.	1.7	31
130	Insights from Computations on the Mechanism of Reduction by Ascorbic Acid of Pt^{IV} Prodrugs with Asplatin and Its Chlorido and Bromido Analogues as Model Systems. Chemistry - A European Journal, 2018, 24, 9572-9580.	1.7	17
131	Bioorthogonal Catalytic Activation of Platinum and Ruthenium Anticancer Complexes by FAD and Flavoproteins. Angewandte Chemie, 2018, 130, 3197-3201.	1.6	25
132	Platinum coordination compounds with potent anticancer activity. Coordination Chemistry Reviews, 2018, 375, 148-163.	9.5	142
133	Synthesis of monofunctional platinum(<scp>iv</scp>) carboxylate precursors for use in Pt(<scp>iv</scp>)â€“peptide bioconjugates. Dalton Transactions, 2018, 47, 15465-15476.	1.6	16

#	Article	IF	Citations
135	Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug. Journal of Inorganic Biochemistry, 2018, 189, 185-191.	1.5	9
136	Naphthalimide Platinum(IV) Compounds as Antitumor Agents with Dual DNA Damage Mechanism to Overcome Cisplatin Resistance. European Journal of Inorganic Chemistry, 2018, 2018, 4442-4451.	1.0	13
137	The cisplatin-based Pt(<scp>iv</scp>)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions. Dalton Transactions, 2018, 47, 8268-8282.	1.6	32
138	Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride. Inorganic Chemistry, 2018, 57, 8227-8235.	1.9	24
139	Probing the Platinum(IV) Prodrug Hypothesis. Are Platinum(IV) Complexes Really Prodrugs of Cisplatin?. Springer Theses, 2018, , 55-71.	0.0	0
140	Pt(IV)/Re(I) Chitosan Conjugates as a Flexible Platform for the Transport of Therapeutic and/or Diagnostic Anticancer Agents. Inorganics, 2018, 6, 4.	1.2	6
141	Dual-acting antitumor Pt(<scp>iv</scp>) prodrugs of kiteplatin with dichloroacetate axial ligands. Dalton Transactions, 2018, 47, 7144-7158.	1.6	21
142	A new platinum-based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells. Life Sciences, 2018, 210, 166-176.	2.0	15
143	Reduction of a platinum(<scp>iv</scp>) prodrug model by sulfur containing biological reductants: computational mechanistic elucidation. Chemical Communications, 2018, 54, 10491-10494.	2.2	17
144	Synthesis, characterization and biological activity of new cyclometallated platinum(<scp>iv</scp>) complexes containing a para-tolyl ligand. Dalton Transactions, 2018, 47, 8956-8971.	1.6	7
146	Platinum(iv) dihydroxido diazido N-(heterocyclic)imine complexes are potently photocytotoxic when irradiated with visible light. Chemical Science, 2019, 10, 8610-8617.	3.7	25
147	Synthesis and Cytotoxic Study of a Platinum(IV) Anticancer Prodrug with Selectivity toward Luteinizing Hormone-Releasing Hormone (LHRH) Receptor-Positive Cancer Cells. Inorganic Chemistry, 2019, 58, 11076-11084.	1.9	20
148	Synthesis and characterisation of platinum(IV) polypyridyl complexes with halide axial ligands. Inorganica Chimica Acta, 2019, 495, 118964.	1.2	9
149	Antiâ€tumor platinum (IV) complexes bearing the antiâ€inflammatory drug naproxen in the axial position. Applied Organometallic Chemistry, 2019, 33, e4763.	1.7	24
150	A potent aminonaphthalimide platinum(IV) complex with effective antitumor activities in vitro and in vivo displaying dual DNA damage effects on tumor cells. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126670.	1.0	13
151	Synthesis and characterization of cyclohexane-1R,2R-diamine-based Pt(<scp>iv</scp>) dicarboxylato anticancer prodrugs: their selective activity against human colon cancer cell lines. Dalton Transactions, 2019, 48, 435-445.	1.6	13
152	Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen â€. International Journal of Molecular Sciences, 2019, 20, 3074.	1.8	31
153	Theoretical exploration of the reduction reaction of monofunctional phenanthriplatin Pt(IV) prodrugs. Inorganica Chimica Acta, 2019, 495, 118951.	1.2	2

#	Article	IF	Citations
154	Transporter and protease mediated delivery of platinum complexes for precision oncology. Journal of Biological Inorganic Chemistry, 2019, 24, 457-466.	1.1	17
155	Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression. Inorganic Chemistry, 2019, 58, 6507-6516.	1.9	47
156	Cytotoxicity and ROS production of novel Pt(IV) oxaliplatin derivatives with indole propionic acid. Inorganica Chimica Acta, 2019, 492, 262-267.	1.2	9
157	A view on multi-action Pt(IV) antitumor prodrugs. Inorganica Chimica Acta, 2019, 492, 32-47.	1.2	71
158	A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton. Journal of Medicinal Chemistry, 2019, 62, 5176-5190.	2.9	48
159	Zweifel an einem Dogma: Hydrolyse Ãquatorialer Liganden von Pt^{IV}â€Komplexen unter physiologischen Bedingungen. Angewandte Chemie, 2019, 131, 7542-7547.	1.6	5
160	Antitumor Platinium(IV) Prodrugs: A Systematic Computational Exploration of Their Reduction Mechanism by <scp>l</scp>-Ascorbic Acid. Inorganic Chemistry, 2019, 58, 3851-3860.	1.9	22
161	Reductions of the cisplatin-based platinum(IV) prodrug cis,cis,trans-[Pt(NH3)2Cl2Br2] by predominant biological thiols: kinetic and mechanistic studies. Transition Metal Chemistry, 2019, 44, 535-544.	0.7	3
162	Glucose-conjugated platinum(IV) complexes as tumor-targeting agents: design, synthesis and biological evaluation. Bioorganic and Medicinal Chemistry, 2019, 27, 1639-1645.	1.4	17
163	A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt^{IV} Complexes under Physiological Conditions. Angewandte Chemie - International Edition, 2019, 58, 7464-7469.	7.2	46
165	Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry, 2019, 88, 102925.	2.0	961
166	Elusive Intermediates in the Breakdown Reactivity Patterns of Prodrug Platinum(IV) Complexes. Journal of the American Society for Mass Spectrometry, 2019, 30, 1881-1894.	1.2	8
167	Development of a series of 4-hydroxycoumarin platinum(IV) hybrids as antitumor agents: Synthesis, biological evaluation and action mechanism investigation. Journal of Inorganic Biochemistry, 2019, 194, 34-43.	1.5	17
168	GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer. Theranostics, 2019, 9, 1047-1065.	4.6	62
169	Synthesis and Cytotoxicity of Water-Soluble Dual- and Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates. Inorganic Chemistry, 2019, 58, 16676-16688.	1.9	13
170	A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes. Angewandte Chemie - International Edition, 2019, 58, 164-167.	7.2	58
171	A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes. Angewandte Chemie, 2019, 131, 170-173.	1.6	15
172	Conjugation between maleimide-containing Pt(IV) prodrugs and furan or furan-containing drug delivery vectors via Diels-Alder cycloaddition. Inorganica Chimica Acta, 2019, 488, 195-200.	1.2	9

#	Article	IF	Citations
173	Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance. Inorganic Chemistry, 2019, 58, 2191-2200.	1.9	45
174	Syntheses, crystal structures and biological evaluation of two new Cu(II) and Co(II) complexes based on (E)-2-(((4H-1,2,4-triazol-4-yl)imino)methyl)-6-methoxyphenol. Journal of Inorganic Biochemistry, 2019, 193, 52-59.	1.5	21
175	Cyclometallated platinum(IV) compounds as promising antitumour agents. Journal of Organometallic Chemistry, 2019, 879, 15-26.	0.8	16
176	Kinetico-mechanistic study on the reduction/complexation sequence of PtIV/PtII organometallic complexes by thiol-containing biological molecules. Inorganica Chimica Acta, 2019, 486, 8-16.	1.2	3
177	Stimuli-Responsive Therapeutic Metallodrugs. Chemical Reviews, 2019, 119, 1138-1192.	23.0	437
178	A metadynamics perspective on the reduction mechanism of the Pt(IV) asplatin prodrug. Journal of Computational Chemistry, 2020, 41, 290-294.	1.5	3
179	Hydrogen halide assisted formation of peptide disulfides by a platinum(IV) complex oxidation in aqueous medium, a mechanistic study. Journal of Molecular Liquids, 2020, 299, 112105.	2.3	3
180	Rational design of anticancer platinum(IV) prodrugs. Advances in Inorganic Chemistry, 2020, 75, 149-182.	0.4	16
181	Spectroscopic, cytotoxicity and molecular docking studies on the interaction between 2,4-dinitrophenylhydrazine derived Schiff bases with bovine serum albumin. Sensors International, 2020, 1, 100048.	4.9	15
182	Fifty years of inorganic biochemistry: Developments, trends, highlights, impact and citations. Journal of Inorganic Biochemistry, 2020, 212, 111230.	1.5	4
183	Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells. Journal of Medicinal Chemistry, 2020, 63, 13861-13877.	2.9	30
184	BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity. Inorganic Chemistry, 2020, 59, 11823-11833.	1.9	42
185	Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs. International Journal of Molecular Sciences, 2020, 21, 4741.	1.8	7
186	Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues. Inorganic Chemistry, 2020, 59, 11676-11687.	1.9	31
187	DNA Nanostructures as Pt(IV) Prodrug Delivery Systems to Combat Chemoresistance. Small, 2020, 16, e2003646.	5.2	25
188	Illuminating Platinum Transportation while Maximizing Therapeutic Efficacy by Gold Nanoclusters via Simultaneous Near-Infrared-I/II Imaging and Glutathione Scavenging. ACS Nano, 2020, 14, 13536-13547.	7.3	181
189	Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer. Inorganic Chemistry, 2020, 59, 12632-12642.	1.9	23
190	trans-Platinum(<scp>iv</scp>) pro-drugs that exhibit unusual resistance to reduction by endogenous reductants and blood serum but are rapidly activated inside cells:¹H NMR and XANES spectroscopy study. Dalton Transactions, 2020, 49, 7722-7736.	1.6	21

#	Article	IF	Citations
192	Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells. Journal of Inorganic Biochemistry, 2020, 210, 111125.	1.5	13
193	Pharmacophore conjugation strategy for multi-targeting metal-based anticancer complexes. Advances in Inorganic Chemistry, 2020, , 257-285.	0.4	3
194	Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7021-7029.	3.3	42
195	Targeting drug delivery system for platinum(â…£)-Based antitumor complexes. European Journal of Medicinal Chemistry, 2020, 194, 112229.	2.6	42
197	Pt(II) versus Pt(IV) in Carbene Glycoconjugate Antitumor Agents: Minimal Structural Variations and Great Performance Changes. Inorganic Chemistry, 2020, 59, 4002-4014.	1.9	32
198	Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects. Molecular Pharmaceutics, 2020, 17, 3009-3023.	2.3	8
199	Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism. Monatshefte FÃ¼r Chemie, 2020, 151, 353-367.	0.9	7
200	Ternary Co(II), Ni(II) and Cu(II) complexes containing dipyridophenazine and saccharin: Structures, reactivity, binding interactions with biomolecules and DNA damage activity. Inorganica Chimica Acta, 2020, 506, 119532.	1.2	16
201	Synthesis, characterization, and antitumor activity of novel tumorâ€targeted platinum(IV) complexes. Applied Organometallic Chemistry, 2020, 34, e5577.	1.7	7
202	Pharmacokinetics and tissue distribution in rats of a novel anticancer platinum compound LLC-1903. Xenobiotica, 2020, 50, 980-987.	0.5	1
203	150 years of the periodic table: New medicines and diagnostic agents. Advances in Inorganic Chemistry, 2020, 75, 3-56.	0.4	16
204	A multi-methodological inquiry of the behavior of cisplatin-based Pt(IV) derivatives in the presence of bioreductants with a focus on the isolated encounter complexes. Journal of Biological Inorganic Chemistry, 2020, 25, 655-670.	1.1	22
205	Platinum(IV) antitumor complexes and their nano-drug delivery. Coordination Chemistry Reviews, 2021, 429, 213640.	9.5	71
206	Cyanide Bridged Platinumâ€Iron Complexes as Cisplatin Prodrug Systems: Design and Computational Study. ChemPhysChem, 2021, 22, 106-111.	1.0	1
207	On the hydrolytic stability of unsymmetric platinum(<scp>iv</scp>) anticancer prodrugs containing axial halogens. Inorganic Chemistry Frontiers, 2021, 8, 3794-3802.	3.0	14
208	Pt(<scp>iv</scp>) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid: synthesis, characterization, cell penetration properties and antitumor activity. Dalton Transactions, 2021, 50, 4663-4672.	1.6	11
209	Platinum-based chemotherapyviananocarriers and co-delivery of multiple drugs. Biomaterials Science, 2021, 9, 6023-6036.	2.6	19
210	Multilayered Modelling of the Metallation of Biological Targets. Lecture Notes in Computer Science, 2021, , 398-412.	1.0	14

#	Article	IF	Citations
211	Cis,cis,trans-[Pt^{IV}Cl₂(NH₃)₂(perillato)₂], a dual-action prodrug with excellent cytotoxic and antimetastatic activity. Dalton Transactions, 2021, 50, 3161-3177.	1.6	8
212	Cell-permeable lanthanideâ€“platinum(<scp>iv</scp>) anti-cancer prodrugs. Dalton Transactions, 2021, 50, 8761-8767.	1.6	6
213	Strategies for the Synthesis of Mono- and Bis-Thionaphthoquinones. Current Organic Synthesis, 2021, 18, 535-546.	0.7	1
214	Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models. Acta Biomaterialia, 2021, 124, 327-335.	4.1	34
215	Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?. Journal of Inorganic Biochemistry, 2021, 217, 111353.	1.5	70
216	Pt(IV) Anticancer Prodrugs â€“ A Tale of Mice and Men. ChemMedChem, 2021, 16, 2188-2191.	1.6	19
217	Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential. Journal of Inorganic Biochemistry, 2021, 218, 111403.	1.5	7
218	Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer. International Journal of Pharmaceutics, 2021, 601, 120577.	2.6	16
219	Dual-target platinum(IV) complexes exhibit antiproliferative activity through DNA damage and induce ER-stress-mediated apoptosis in A549 cells. Bioorganic Chemistry, 2021, 110, 104741.	2.0	7
220	Can the Self-Assembling of Dicarboxylate Pt(IV) Prodrugs Influence Their Cell Uptake?. Bioinorganic Chemistry and Applications, 2021, 2021, 1-8.	1.8	1
221	Disulfide bond based cascade reduction-responsive Pt(IV) nanoassemblies for improved anti-tumor efficiency and biosafety. Colloids and Surfaces B: Biointerfaces, 2021, 203, 111766.	2.5	17
222	Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?. Journal of Medicinal Chemistry, 2021, 64, 11364-11378.	2.9	30
223	Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs. Coordination Chemistry Reviews, 2021, 442, 213991.	9.5	89
224	Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein. European Journal of Medicinal Chemistry, 2021, 221, 113520.	2.6	13
225	A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction. Journal of Controlled Release, 2021, 338, 358-366.	4.8	18
226	Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate. European Journal of Medicinal Chemistry, 2021, 223, 113730.	2.6	19
227	Iodido equatorial ligands influence on the mechanism of action of Pt(IV) and Pt(II) antiâ€cancer complexes: A DFT computational study. Journal of Computational Chemistry, 2021, 42, 608-619.	1.5	9
228	Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin inÂvivo and inÂvitro. Drug Delivery, 2021, 28, 1272-1280.	2.5	11

#	Article	IF	Citations
229	Translational Theragnosis of Ovarian Cancer: where do we stand?. Current Medicinal Chemistry, 2020, 27, 5675-5715.	1.2	25
230	Zinc-Containing Metalloenzymes: Inhibition by Metal-Based Anticancer Agents. Frontiers in Chemistry, 2020, 8, 402.	1.8	29
231	An erythrocyte-delivered photoactivatable oxaliplatin nanoprodrug for enhanced antitumor efficacy and immune response. Chemical Science, 2021, 12, 14353-14362.	3.7	15
232	Photochemistry and in vitro anticancer activity of Pt(<scp>iv</scp>)Re(<scp>i</scp>) conjugates. Chemical Communications, 2021, 57, 11189-11192.	2.2	10
233	Research progress of azido-containing Pt(IV) antitumor compounds. European Journal of Medicinal Chemistry, 2022, 227, 113927.	2.6	17
234	Anticancer Activity of Platinum (II) Complex with 2-Benzoylpyridine by Induction of DNA Damage, S-Phase Arrest, and Apoptosis. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 504-517.	0.9	2
235	Ultrasoundâ€Triggered Delivery of Iproplatin from Microbubbleâ€Conjugated Liposomes. ChemistryOpen, 2021, 10, 1170-1176.	0.9	11
236	Computational strategies to model the interaction and the reactivity of biologically-relevant transition metal complexes. Inorganica Chimica Acta, 2022, 530, 120686.	1.2	20
237	Reduction of an asymmetric Pt(IV) prodrug fac-[Pt(dach)Cl3(OC(=O)CH3)] by biological thiol compounds: kinetic and mechanistic characterizations. Transition Metal Chemistry, 2021, 46, 623-631.	0.7	1
238	Electron Delocalization in Spectroelectrochemically and Computationally Characterized [Pt{(p-BrC₆F₄)NCHâ•C(Cl)NEt₂}Cl(py)]⁺ Formed by Electrochemical Oxidation of [Pt^{II}{(p-BrC₆F₄)NCHâ•C(Cl)NEt₂}Cl(py)]. Inorganic Chemistry, 2021, 60, 18899-18911.	1.9	1
239	Dendrimers and dendritic nanoparticles for stimuli-responsive nanomedicine. , 2022, , 119-131.		1
240	Pt(<scp>iv</scp>) antitumor prodrugs: dogmas, paradigms, and realities. Dalton Transactions, 2022, 51, 2121-2134.	1.6	40
241	The influence of different carbonate ligands on the hydrolytic stability and reduction of platinum(<scp>iv</scp>) prodrugs. Dalton Transactions, 2022, 51, 885-897.	1.6	5
242	Formulations of highly antiproliferative hydrophobic Pt(IV) complexes into lipidic nanoemulsions as delivery vehicles. Inorganica Chimica Acta, 2022, 535, 120859.	1.2	3
243	Metallodrugs in cancer nanomedicine. Chemical Society Reviews, 2022, 51, 2544-2582.	18.7	70
244	A platinum-based fluorescent â€œturn onâ€•sensor to decipher the reduction of platinum(<scp>iv</scp>) prodrugs. Dalton Transactions, 2022, 51, 5394-5398.	1.6	7
245	Synthesis and characterization of thiocarbonato-linked platinum(<scp>iv</scp>) complexes. Dalton Transactions, 2022, 51, 5567-5576.	1.6	6
246	Application of the anthraquinone drug rhein as an axial ligand in bifunctional Pt(<scp>iv</scp>) complexes to obtain antiproliferative agents against human glioblastoma cells. Dalton Transactions, 2022, 51, 6014-6026.	1.6	1

#	Article	IF	Citations
247	Enhancing Circulation and Tumor Accumulation of Carboplatin via an Erythrocyteâ€Anchored Prodrug Strategy. Angewandte Chemie, 0, , .	1.6	3
248	Enhancing Circulation and Tumor Accumulation of Carboplatin via an Erythrocyteâ€Anchored Prodrug Strategy. Angewandte Chemie - International Edition, 2022, 61, .	7.2	17
249	3D printed drug-loaded implantable devices for intraoperative treatment of cancer. Journal of Controlled Release, 2022, 344, 147-156.	4.8	10
250	Photo-Enhanced Chemotherapy Performance in Bladder Cancer Treatment via Albumin Coated AIE Aggregates. ACS Nano, 2022, 16, 7535-7546.	7.3	37
251	Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin(IV) Derivatives. Molecular Pharmaceutics, 2022, 19, 1325-1337.	2.3	5
252	Synthesis, Characterization and Crystal Structure of Platinum(IV) Complex as a Potent Anticancer Agent and an Efficient Catalyst. SSRN Electronic Journal, 0, , .	0.4	0
253	Hitting Multiple Cellular Targets in Triple-Negative Breast Cancer Using Dual-Action Cisplatin(IV) Prodrugs for Safer Synergistic Chemotherapy. ACS Biomaterials Science and Engineering, 2022, 8, 2349-2362.	2.6	7
254	A Theoretical Study on the Medicinal Properties and Eletronic Structures of Platinum(IV) Anticancer Agents With Cl Substituents. Frontiers in Oncology, 2022, 12, .	1.3	0
255	Construction of size-transformable supramolecular nano-platform against drug-resistant colorectal cancer caused by Fusobacterium nucleatum. Chemical Engineering Journal, 2022, 450, 137605.	6.6	13
256	Potential Anticancer Activities and Catalytic Oxidation Efficiency of Platinum(IV) Complex. Molecules, 2022, 27, 4406.	1.7	5
257	Heavy-Metal Trojan Horse: Enterobactin-Directed Delivery of Platinum(IV) Prodrugs toEscherichia coli. Journal of the American Chemical Society, 2022, 144, 12756-12768.	6.6	26
258	Computational Exploration of the Synergistic Anticancer Effect of a Multi-Action Ru(II)â€“Pt(IV) Conjugate. Inorganic Chemistry, 2022, 61, 12903-12912.	1.9	9
259	Targeting of the intracellular redox balance by metal complexes towards anticancer therapy. Frontiers in Chemistry, 0, 10, .	1.8	13
260	Oxoplatinâ€Based Pt(IV) Lipoate Complexes and Their Biological Activity. Chemistry and Biodiversity, 2022, 19, .	1.0	6
261	Leveraging the photophysical properties of rhenium(I) tricarbonyl complexes for biomedical applications. Advances in Inorganic Chemistry, 2022, , 1-33.	0.4	2
262	Novel oxaliplatin(<scp>iv</scp>) complexes conjugated with ligands bearing pendant 1,2-dithiolane/1,2-diselenolane/cyclopentyl motifs. Dalton Transactions, 2022, 51, 16824-16835.	1.6	4
263	Potent Chlorambucil-Platinum(IV) Prodrugs. International Journal of Molecular Sciences, 2022, 23, 10471.	1.8	11
264	Blood Components as Carriers for Smallâ€Molecule Platinum Anticancer Drugs. ChemMedChem, 2022, 17, .	1.6	1

#	Article	IF	Citations
265	Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy. Frontiers in Pharmacology, 0, 13, .	1.6	3
266	Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates. Molecules, 2022, 27, 7120.	1.7	7
267	Pt(IV) Complex Selectively Oxidizes alpha-Synuclein Methionine Disclosed by NMR. Inorganic Chemistry Frontiers, 0, , .	3.0	0
268	Dual-Action Pt(IV) Prodrugs and Targeted Delivery in Metal-Organic Frameworks: Overcoming Cisplatin Resistance and Improving Anticancer Activity. Bulletin of the Chemical Society of Japan, 2022, 95, 1561-1577.	2.0	8
269	A Pt(IV)-conjugated brain penetrant macrocyclic peptide shows pre-clinical efficacy in glioblastoma. Journal of Controlled Release, 2022, 352, 623-636.	4.8	5
271	Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs. International Journal of Molecular Sciences, 2022, 23, 14511.	1.8	6
272	Novel Platinum(II) and Platinum(IV) Antitumor Agents that Exhibit Potent Cytotoxicity and Selectivity. Journal of Medicinal Chemistry, 2022, 65, 16481-16493.	2.9	7
273	Oral Anticancer Heterobimetallic PtIVâ€AuI Complexes Show High In Vivo Activity and Low Toxicity. Angewandte Chemie, 0, , .	1.6	0
274	Biotinylated Pt(<scp>iv</scp>) prodrugs with elevated lipophilicity and cytotoxicity. Dalton Transactions, 2023, 52, 866-871.	1.6	3
275	An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies. Inorganica Chimica Acta, 2023, 548, 121388.	1.2	8
276	Oral Anticancer Heterobimetallic Pt^{IV}â^'Au^IComplexes Show High In Vivo Activity and Low Toxicity. Angewandte Chemie - International Edition, 2023, 62, .	7.2	9
277	The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CH3COO)Cl2(NH3)2(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake. Bioinorganic Chemistry and Applications, 2022, 2022, 1-15.	1.8	12
278	Molecular design and synthesis of dithiocarbazate-based potential biomaterials: Crystal structure, apoptotic activity and protein binding studies. Journal of Molecular Structure, 2023, 1285, 135388.	1.8	1
279	Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment. European Journal of Medicinal Chemistry, 2023, 250, 115233.	2.6	4
280	Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrugâ€"Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines. International Journal of Molecular Sciences, 2023, 24, 5718.	1.8	2
281	Platinum(IV)-Loaded Degraded Glycol Chitosan as Efficient Platinum(IV) Drug Delivery Platform. Pharmaceutics, 2023, 15, 1050.	2.0	2
282	Identification of Hypoxia-Targeting Drugs in the Tumor Microenvironment and Prodrug Strategies for Targeting Tumor Hypoxia. , 2023, , 369-401.		0
301	Pt(<scp>iv</scp>) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?. Inorganic Chemistry Frontiers, 2024, 11, 1639-1667.	3.0	1

#	Article	IF	Citations